mounjaro es tirzepatide New version of diabetes drug approved for weight loss by FDA la FDA aprueba tirzepatida (Mounjaro)

By the end of week 3, approximately 60-70% of patients report significant improvement

Analysts were hoping for a safety profile similar to what was achieved in Phase II

Potential of gamma/delta T cells for solid tumor immunotherapy

Better metrics during tirzepatide treatment: Body composition measurements (DEXA scan, bioimpedance scale, or even waist-to-hip ratio) Strength benchmarks (can you lift what you lifted last month?) Energy diaries (rate energy 1 to 10 daily to track trends) Grip strength (a reliable proxy for overall muscle function) Walking speed (declining walking speed correlates with lean mass loss) If your weight is going down but your strength is maintained and energy is stable, you are losing primarily fat